HCWB Company Profile and Key Details

HCW Biologics Inc. generated EPS of -$13.96 over the past year. Five-year average earnings growth is -29.55%. Wall Street analysts project EPS growth of 68.64% annually over the next five years. The latest quarter delivered EPS of $0.37. The next quarter is forecast at -$0.84. Next year's EPS is expected at $0.92. HCW Biologics Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 14, 2026, missed forecasts by -184.09%. The prior quarter beat by 213.1%. Over the last six quarters, Apple has recorded several small beats. These include -23.08% in November 14, 2024.

HCWB has shown mixed momentum, gaining 10.66% over the past week and -66.17% over the past quarter, though year-to-date performance is up 39.09%. Short-term trend indicators are bullishly aligned (SMA20 -34.31%, SMA50 -51.84%, SMA200 -84.75%). The stock’s 14-day RSI is 23.26 (weak momentum), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.91% below its high and over 4.69% above its low. Average 10-day trading volume of 1.98 million shares is below the 3-month average of 9.92 million, indicating normal recent market interest.

HCW Biologics Inc. has 2.15 million shares outstanding. The public float is 1.14 million shares, elevated short interest at 3.73% of float. This equals 77.82 thousand shares. The short ratio is 0.68 days. Institutional investors hold 1.38% of the float. Insiders own 27.3%. Wong Hing C holds 501.91 thousand shares, Rhode Peter has 46.78 thousand shares and Byam Rebecca has 43.01 thousand shares.

HCW Biologics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.36. This means the shares are trading below this model’s fair value.

HCW Biologics Inc. (NASDAQ:HCWB) closed at $0.34 USD, losing -$0.01 (-3.55%) from the previous close of $0.35. The stock is currently mid-range between its 52-week high and low $0.25 and $10.00. With a market capitalization of about $702.93 thousand, HCW Biologics Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.14). Key stats such as the average daily volume over the past year has been around 9.33 million shares, volume is running light vs its 52-week average. Headquartered in Miramar, FL, HCW Biologics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Hing C. Wong, the company employs approximately 36 people and listed since July 20, 2021. HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.

HCW Biologics Inc. trades at a P/E ratio of -0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 13.09 and a price-to-book ratio of 0.26 suggesting the stock is closer to book value. The P/FCF stands at -0.05, also above market averages.

HCW Biologics Inc. (NASDAQ:HCWB) shares are up 39.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows HCW Biologics Inc. trading at a premium to the broader market with a P/E of -0.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.80, suggesting 2511.28% upside. Our AI forecast model points to short-term weakness (-2.08% over two weeks), a medium-term fall (-94.07% over three months), and a longer-term loss (-88.13% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that HCW Biologics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.08%, with price expected at $0.33 by May 28, 2026, within a range of $0.24 to $0.43 3-Month Outlook: Projected fall of -94.07%, reaching $0.02 by August 12, 2026, with a range of $0.00 to $0.48. 1-Year Outlook: Projected loss of -88.13%, with price at $0.04 by May 14, 2027, within a range of $0.00 to $0.84.